| Exosomes as diagnostic and predictive biomarkers in lung cancer P Reclusa, S Taverna, M Pucci, E Durendez, S Calabuig, P Manca, ... Journal of thoracic disease 9 (Suppl 13), S1373, 2017 | 117 | 2017 |
| Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ... Nature Medicine 28 (8), 1612-1618, 2022 | 115 | 2022 |
| Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer C Rolfo, P Manca, R Salgado, P Van Dam, A Dendooven, JF Gandia, ... ESMO open 3 (5), e000398, 2018 | 94 | 2018 |
| Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ... Journal of Clinical Oncology 39 (15_suppl), 3506-3506, 2021 | 64 | 2021 |
| Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer D de Miguel-Perez, A Russo, O Arrieta, M Ak, F Barron, M Gunasekaran, ... Journal of Experimental & Clinical Cancer Research 41 (1), 186, 2022 | 52 | 2022 |
| Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions M Fioramonti, D Santini, M Iuliani, G Ribelli, P Manca, N Papapietro, ... Oncotarget 8 (12), 20113, 2017 | 39 | 2017 |
| Determinants of bone specific metastasis in prostate cancer P Manca, F Pantano, M Iuliani, G Ribelli, D De Lisi, R Danesi, M Del Re, ... Critical Reviews in Oncology/Hematology 112, 59-66, 2017 | 22 | 2017 |
| Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint … G Fucà, F Corti, M Ambrosini, R Intini, M Salati, E Fenocchio, P Manca, ... Journal for Immunotherapy of Cancer 9 (4), 2021 | 19 | 2021 |
| Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy G Randon, G Maddalena, MM Germani, CC Pircher, P Manca, F Bergamo, ... JCO Precision Oncology 6, e2200037, 2022 | 18 | 2022 |
| Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal … P Manca, S Corallo, S Lonardi, G Fucà, A Busico, AG Leone, F Corti, ... British Journal of Cancer 126 (3), 449-455, 2022 | 18 | 2022 |
| Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer P Manca, S Corallo, G Randon, S Lonardi, C Cremolini, L Rimassa, ... European Journal of Cancer 144, 31-40, 2021 | 18 | 2021 |
| Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer G Randon, R Intini, C Cremolini, E Elez, MJ Overman, J Lee, P Manca, ... European Journal of Cancer 161, 90-98, 2022 | 16 | 2022 |
| EGFR Amplification in Metastatic Colorectal Cancer G Randon, R Yaeger, JF Hechtman, P Manca, G Fucà, H Walch, J Lee, ... JNCI: Journal of the National Cancer Institute 113 (11), 1561-1569, 2021 | 16 | 2021 |
| Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild … R Moretto, D Rossini, I Capone, A Boccaccino, F Perrone, E Tamborini, ... Clinical Colorectal Cancer 20 (4), 314-317, 2021 | 15 | 2021 |
| Circulating tumor DNA as a marker of minimal residual disease after radical resection of colorectal liver metastases F Marmorino, M Prisciandaro, M Giordano, E Ortolan, S Crucitta, P Manca, ... JCO precision oncology 6, e2200244, 2022 | 14 | 2022 |
| Large-scale profiling of extracellular vesicles identified miR-625-5p as a novel biomarker of immunotherapy response in advanced non-small-cell lung cancer patients F Pantano, F Zalfa, M Iuliani, S Simonetti, P Manca, A Napolitano, S Tiberi, ... Cancers 14 (10), 2435, 2022 | 14 | 2022 |
| The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer P Manca, S Corallo, A Busico, S Lonardi, F Corti, C Antoniotti, L Procaccio, ... Clinical Cancer Research 27 (9), 2505-2514, 2021 | 14 | 2021 |
| The value of immunotherapy in head and neck cancer P Manca, LE Raez, M Salzberg, J Sanchez, B Hunis, C Rolfo Expert Opinion on Biological Therapy 19 (1), 35-43, 2019 | 14 | 2019 |
| Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies A Russo, AF Cardona, C Caglevic, P Manca, A Ruiz-Patiño, O Arrieta, ... Translational Lung Cancer Research 9 (6), 2581, 2020 | 13 | 2020 |
| Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers MP Rubinstein, C Williams, C Mart, J Beall, L MacPherson, J Azar, ... The Journal of Immunology 208 (6), 1362-1370, 2022 | 12 | 2022 |
Filippo PietrantonioVerified email at istitutotumori.mi.it
